0
Orphan Designations
3
FDA Approvals
Latest: NILOTINIB (2025)
0
Active Trials
2
Rare Diseases
across 3 areas
0
News (30d)
Quiet
Cipla USA Inc. is a company with 0 orphan drug designations across 2 rare diseases, including 3 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| blast phase chronic myelogenous leukemia, BCR-ABL1 positive | NILOTINIB | Des.TrialAppr. |
| chronic myelogenous leukemia, BCR-ABL1 positive | NILOTINIB | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio